iData Insights

XTL Biopharmaceuticals Ltd. - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 08, 2016 17:21 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of XTL Biopharmaceuticals Ltd.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of XTL Biopharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of XTL Biopharmaceuticals Ltd.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the XTL Biopharmaceuticals Ltd.s pipeline products Reasons to buy - Evaluate XTL Biopharmaceuticals Ltd.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of XTL Biopharmaceuticals Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the XTL Biopharmaceuticals Ltd. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of XTL Biopharmaceuticals Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of XTL Biopharmaceuticals Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of XTL Biopharmaceuticals Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179144/xtl-biopharmaceuticals-ltd-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179144/xtl-biopharmaceuticals-ltd-product-pipeline-review-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

XTL Biopharmaceuticals Ltd. Snapshot 5

XTL Biopharmaceuticals Ltd. Overview 5

Key Information 5

Key Facts 5

XTL Biopharmaceuticals Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

XTL Biopharmaceuticals Ltd. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

XTL Biopharmaceuticals Ltd. - Pipeline Products Glance 12

XTL Biopharmaceuticals Ltd. - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

XTL Biopharmaceuticals Ltd. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

XTL Biopharmaceuticals Ltd. - Drug Profiles 16

edratide 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

SAM-101 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Erythropoietin (recombinant) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

PRT-0467 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

XTL Biopharmaceuticals Ltd. - Pipeline Analysis 20

XTL Biopharmaceuticals Ltd. - Pipeline Products by Target 20

XTL Biopharmaceuticals Ltd. - Pipeline Products by Route of Administration 21

XTL Biopharmaceuticals Ltd. - Pipeline Products by Molecule Type 22

XTL Biopharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 23

XTL Biopharmaceuticals Ltd. - Recent Pipeline Updates 24

XTL Biopharmaceuticals Ltd. - Dormant Projects 26

XTL Biopharmaceuticals Ltd. - Discontinued Pipeline Products 27

Discontinued Pipeline Product Profiles 27

bicifadine hydrochloride 27

edratide 27

XTL Biopharmaceuticals Ltd. - Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

XTL Biopharmaceuticals Ltd. Snapshot 5

XTL Biopharmaceuticals Ltd. Overview 5

Key Information 5

Key Facts 5

XTL Biopharmaceuticals Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

XTL Biopharmaceuticals Ltd. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

XTL Biopharmaceuticals Ltd. - Pipeline Products Glance 12

XTL Biopharmaceuticals Ltd. - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

XTL Biopharmaceuticals Ltd. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

XTL Biopharmaceuticals Ltd. - Drug Profiles 16

edratide 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

SAM-101 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Erythropoietin (recombinant) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

PRT-0467 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

XTL Biopharmaceuticals Ltd. - Pipeline Analysis 20

XTL Biopharmaceuticals Ltd. - Pipeline Products by Target 20

XTL Biopharmaceuticals Ltd. - Pipeline Products by Route of Administration 21

XTL Biopharmaceuticals Ltd. - Pipeline Products by Molecule Type 22

XTL Biopharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 23

XTL Biopharmaceuticals Ltd. - Recent Pipeline Updates 24

XTL Biopharmaceuticals Ltd. - Dormant Projects 26

XTL Biopharmaceuticals Ltd. - Discontinued Pipeline Products 27

Discontinued Pipeline Product Profiles 27

bicifadine hydrochloride 27

edratide 27

XTL Biopharmaceuticals Ltd. - Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

Read More http://www.idatainsights.com/reports-landing-page.php?id=179144/xtl-biopharmaceuticals-ltd-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.